Matangazo

Utafiti wa Ischgl: Ukuzaji wa Kinga ya Mifugo na Mkakati wa Chanjo dhidi ya COVID-19

Routine sero-surveillance of the idadi ya watu to estimate presence of kingamwili kwa Covid-19 is required to understand the development of kundi kinga in a population. Data from the sero-surveillance study of population in the Ischgl town of Austria throws light on this aspect and have led researchers to develop a prediction model which could help plan an effective vaccine strategy and non-invasive population interventions against the infection. 

The data from Ischgl study demonstrated that approx. 42.4% of the population were sero-positive after 9-10 months of testing since first wagonjwa were exposed to the korona virusi1,2. Hata hivyo, hili linahitaji matumizi ya kingamwili zinazofaa na shabaha sahihi ili kuhakikisha kwamba watu walio na maambukizo madogo hawakosi.3. This data from the Ischgl study suggests that the antibody response to Covid-19 is not only long lasting but can be a predictor of kundi kinga in a population. This, in turn, necessitates the need for a routine sero-surveillance in a population to estimate the number of people who are antibody positive? Although this study may not be representative of the entire population, however, it can still help us in identifying, not only the sero-positive individuals, but indirectly leads to predicting the estimated population that would require a booster vaccine dose or not. This is of extreme importance at this moment, given the fact that vaccine administration against Covid-19 is in full swing in most countries and the world is waiting anxiously to return to the “normal life” that existed before COVID-19. This will enable the policy makers and administrators to develop guidelines and ensure adequate health care resources are spent towards the population where antibody development is minimal. 

Aidha, utafiti huu pia umefunua maendeleo ya mfano wa utabiri usio na uvamizi kulingana na tathmini ya kibinafsi ya dalili tatu zilizotambuliwa (kikohozi, kupoteza ladha / harufu na maumivu ya viungo) ambayo inaweza kutabiri kwa usahihi watu binafsi sero-chanya.4 katika idadi ya watu ambao wameambukizwa na coronavirus. Unyonyaji wa mtindo kama huo usiovamizi unaweza kweli kuwa wa manufaa kwa ulimwengu mzima kupigana na janga la COVID-19 kwa kutabiri hali chanya katika idadi ya watu. 

Kuchanganya njia hizi zote mbili za uchunguzi wa kawaida wa sero na muundo wa utabiri kwa kutumia programu ya CHES.5 ili kubaini uthabiti wa sero-chanya, nchi kote ulimwenguni zinaweza kupanga kwa ufanisi tafiti za uchunguzi wa sero ambazo zinaweza kusaidia katika kudhibiti janga hili kwa kutumia pesa za walipa kodi kwa ufanisi zaidi na kurudisha hali ya kawaida haraka iwezekanavyo.  

*** 

Marejeo:

  1. Ischgl: Kingamwili zimepungua kidogo tu. Ilichapishwa mtandaoni tarehe 18 Februari 2021. Inapatikana kwa https://tirol.orf.at/stories/3090797/ Ilifikiwa tarehe 19 Februari 2021.  
  1. Chuo Kikuu cha Matibabu cha Innsbruck 2021. Taarifa kwa vyombo vya habari - Utafiti wa Ischgl: asilimia 42.4 wana kingamwili. Inapatikana mtandaoni kwa https://www.i-med.ac.at/pr/presse/2020/40.html Ilifikiwa tarehe 19 Februari 2021.  
  1. Je, tunadharau kuenea kwa SARS-CoV2. BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3364 (Imechapishwa 03 Septemba 2020) 
  1. Lehmann, J., Giesinger, et al., 2021. Inakadiria kuenea kwa kingamwili za SARS-CoV-2 kwa kutumia dalili tatu zilizoripotiwa zenyewe: Uundaji wa muundo wa utabiri kulingana na data kutoka Ischgl, Austria. Epidemiolojia na Maambukizi, 1-13. Imechapishwa mtandaoni na Cambridge University Press: 18 Februari 2021. DOI: https://doi.org/10.1017/S0950268821000418 
  1. Holzner B, Giesinger JM, Pinggera J, Zugal S, Schöpf F, Oberguggenberger AS, Gamper EM, Zabernigg A, Weber B, Rumpold G. Programu ya Tathmini ya Afya ya Kompyuta (CHES): programu ya ufuatiliaji wa matokeo yanayoripotiwa na mgonjwa kielektroniki. . BMC Med Mjulishe Decis Mak. 2012 Nov 9; 12:126. doi: https://doi.org/10.1186/1472-6947-12-126.  

***

Rajeev Soni
Rajeev Sonihttps://www.RajeevSoni.org/
Dk. Rajeev Soni (Kitambulisho cha ORCID : 0000-0001-7126-5864) ana Ph.D. katika Bioteknolojia kutoka Chuo Kikuu cha Cambridge, Uingereza na ana uzoefu wa miaka 25 wa kufanya kazi duniani kote katika taasisi mbalimbali na mashirika ya kimataifa kama vile Taasisi ya Utafiti ya Scripps, Novartis, Novozymes, Ranbaxy, Biocon, Biomerieux na kama mpelelezi mkuu katika Maabara ya Utafiti wa Jeshi la Marekani. katika ugunduzi wa dawa, uchunguzi wa molekuli, usemi wa protini, utengenezaji wa kibayolojia na ukuzaji wa biashara.

Kujiunga na jarida letu

Ili kusasishwa na habari zote za hivi punde, matoleo na matangazo maalum.

Wengi Mpya Makala

Mababu wa Kinasaba na Wazao wa Ustaarabu wa Bonde la Indus

Ustaarabu wa Harappan haukuwa mchanganyiko wa hivi majuzi...

Msaada kutoka kwa Ugonjwa wa Neuropathy wa Maumivu Kupitia Kuondoa Mishipa Iliyoharibika Kiasi

Wanasayansi wamepata njia mpya katika panya...

Je, Kula Kiamsha kinywa Mara kwa Mara Husaidia Kweli Kupunguza Uzito wa Mwili?

Uhakiki wa majaribio ya hapo awali unaonyesha kuwa kula au ...
- Matangazo -
94,471Mashabikikama
47,678Wafuasikufuata
1,772Wafuasikufuata
30WanachamaKujiunga